

Sri Lanka

Population 2018

21 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	14 (10–18)	64 (47–83)
HIV-positive TB incidence	0.056 (0.034–0.084)	0.27 (0.16–0.4)
MDR/RR-TB incidence ^{oo}	0.026 (<0.01–0.079)	0.12 (0.01–0.37)
HIV-negative TB mortality	0.81 (0.66–0.98)	3.8 (3.1–4.6)
HIV-positive TB mortality	0.018 (0.011–0.028)	0.09 (0.05–0.13)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	0.1% (0–0.5)
Previously treated cases	3.3% (1.8–5.5)

TB case notifications, 2018

Total new and relapse	8 620
- % tested with rapid diagnostics at time of diagnosis	2%
- % with known HIV status	92%
- % pulmonary	71%
- % bacteriologically confirmed ^{ooo}	73%
- % children aged 0-14 years	3%
- % women	34%
- % men	63%
Total cases notified	8 856

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	64% (49–86)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	6% (4–9)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	34	<1%
- on antiretroviral therapy	34	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	30%
- Previously treated cases	91%
Laboratory-confirmed cases*	MDR/RR-TB: 32, XDR-TB: 1
Patients started on treatment**	MDR/RR-TB: 13, XDR-TB: 1
MDR/RR-TB cases tested for resistance to second-line drugs	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	85%	8 328
Previously treated cases, excluding relapse, registered in 2017	70%	183
HIV-positive TB cases registered in 2017	69%	29
MDR/RR-TB cases started on second-line treatment in 2016	65%	17
XDR-TB cases started on second-line treatment in 2016	0	0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	32%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	48% (44–52)

TB financing, 2019

National TB budget (US\$ millions)	5.1
Funding source: 70% domestic, 30% international, 0% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females ■ Males Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically